Abstract-Estradiol inhibits smooth muscle cell growth; however, the mechanisms involved remain unclear. Because estradiol stimulates cAMP synthesis and adenosine inhibits cell growth, we hypothesized that the conversion of cAMP to adenosine (ie, the cAMP-adenosine pathway) mediates in part the inhibitory effects of estradiol on vascular smooth muscle cell growth. To test this hypothesis, we examined the effects of estradiol (0.001 to 1 mol/L) on serum-induced DNA, collagen, and total protein synthesis and cell number in the absence and presence of 1,3-dipropyl-8-psulfophenylxanthine (10 nmol/L; A 1 /A 2 adenosine receptor antagonist), KF17837 (10 nmol/L; selective A 2 adenosine receptor antagonist), 8-cyclopentyl-1,3-dipropylxanthine (10 nmol/L; selective A 1 adenosine receptor antagonist), and 2Ј,5Ј-dideoxyadenosine (10 mol/L; adenylyl cyclase inhibitor). Estradiol inhibited all measures of cell growth, and the concentration-dependent inhibitory curves for estradiol were shifted to the right (PϽ0.05) by 1,3-dipropyl-8-psulfophenylxanthine, KF17837, and 2Ј,5Ј-dideoxyadenosine but not by 8-cyclopentyl-1,3-dipropylxanthine. Moreover, the inhibitory effects of estradiol were enhanced by stimulation of adenylyl cyclase with forskolin and by inhibition of adenosine metabolism with erythro-9-(2-hydroxy-3-nonyl)adenine plus iodotubericidin (adenosine deaminase and kinase inhibitors, respectively). Estradiol also increased levels of cAMP and adenosine, and these effects were blocked by 2Ј,5Ј-dideoxyadenosine (PϽ0.05). Our results support the hypothesis that estradiol stimulates cAMP synthesis and cAMP-derived adenosine regulates smooth muscle cell growth via A 2 adenosine receptors. Thus, the cAMP-adenosine pathway may contribute importantly to the antivasooclusive effects of estradiol. 7␤-Estradiol is a potent inhibitor of vascular smooth muscle cell (SMC) growth 1-4 ; however, the mechanisms responsible for this inhibitory effect remain unclear. Recent studies from our group demonstrate that adenosine via the A 2 receptor is an effective inhibitor of vascular SMC growth [5] [6] [7] and that in vascular SMCs, cAMP is an important determinant of adenosine production via a biochemical mechanism we refer to as the cAMP-adenosine pathway. 6 This pathway involves the conversion of cAMP to AMP and hence to adenosine by the enzymes phosphodiesterase and 5Ј-nucleotidase, respectively. Moreover, our studies show that the inhibitory effects of exogenous cAMP on SMC growth are blocked by antagonism of A 2 receptors, 6 thus implying that the cAMP-adenosine pathway regulates SMC growth. Since 17␤-estradiol increases cAMP levels in vascular SMCs, 8 it is possible that the inhibitory effects of estradiol on SMC growth are mediated in part by the cAMP-adenosine pathway. This hypothesis was tested in the present study by determining whether estradiol increases cAMP and adenosine levels in SMCs via a mechanism that is blocked by inhibition of adenylyl cyclase, by determining whether the inhibitory effects of estradiol on SMC growth are blocked by inhibition of adenylyl cyclase and antagonism of adenosine receptors, and by determining whether the effects of estradiol on SMC growth and adenosine levels are augmented by preventing the conversion of adenosine to inactive metabolites.
1
7␤-Estradiol is a potent inhibitor of vascular smooth muscle cell (SMC) growth [1] [2] [3] [4] ; however, the mechanisms responsible for this inhibitory effect remain unclear. Recent studies from our group demonstrate that adenosine via the A 2 receptor is an effective inhibitor of vascular SMC growth [5] [6] [7] and that in vascular SMCs, cAMP is an important determinant of adenosine production via a biochemical mechanism we refer to as the cAMP-adenosine pathway. 6 This pathway involves the conversion of cAMP to AMP and hence to adenosine by the enzymes phosphodiesterase and 5Ј-nucleotidase, respectively. Moreover, our studies show that the inhibitory effects of exogenous cAMP on SMC growth are blocked by antagonism of A 2 receptors, 6 thus implying that the cAMP-adenosine pathway regulates SMC growth. Since 17␤-estradiol increases cAMP levels in vascular SMCs, 8 it is possible that the inhibitory effects of estradiol on SMC growth are mediated in part by the cAMP-adenosine pathway. This hypothesis was tested in the present study by determining whether estradiol increases cAMP and adenosine levels in SMCs via a mechanism that is blocked by inhibition of adenylyl cyclase, by determining whether the inhibitory effects of estradiol on SMC growth are blocked by inhibition of adenylyl cyclase and antagonism of adenosine receptors, and by determining whether the effects of estradiol on SMC growth and adenosine levels are augmented by preventing the conversion of adenosine to inactive metabolites.
Methods

Aortic SMC Culture
Aortic SMCs were cultured as explants from the descending abdominal aortas obtained from anesthetized Sprague-Dawley male rats (Charles River, Wilmington, Mass) as described previously. 7 SMC purity was characterized as described in detail previously. 7 SMCs in primary cultures or first passage were used for all the experiments.
Treatments
DNA, collagen, total protein synthesis, and cell proliferation studies were performed under the following treatments: (1) 17␤-estradiol; (2) 17␤-estradiol plus 8-cyclopentyl-1,3-dipropylxanthine (DPCPX, a selective A 1 receptor antagonist); (3) 17␤-estradiol plus KF17837 (a selective A 2 receptor antagonist); (4) 17␤-estradiol plus 1,3-dipropyl-8-p-sulfophenylxanthine (DPSPX, a nonselective A 1 /A 2 adenosine receptor antagonist); (5) 17␤-estradiol plus erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA, an inhibitor of adenosine deaminase) plus iodotubericidin (an adenosine kinase inhibitor); (6) 17␤-estradiol plus (R)-p-adenosine 3Ј,5Ј-cyclic phosphorothioate (Rp-cAMP, cAMP-dependent protein kinase A inhibitor); (7) 17␤-estradiol plus 2Ј,5Ј-dideoxyadenosine (DDA, adenylyl cyclase inhibitor), (8) EHNA plus iodotubericidin; (9) DPCPX; (10) DPSPX; (11) KF17837; (12) DDA; and (13) 3 H]L-proline (1 Ci/mL). The experiments were terminated by washing the cells twice with Dulbecco's PBS and twice with ice-cold trichloroacetic acid (10%). The precipitate was solubilized in 500 L of 0.3N NaOH and 0.1% SDS after incubation at 50°C for 2 hours. Aliquots from 4 wells for each treatment with 10 mL scintillation fluid were counted in a liquid scintillation counter, and each experiment was conducted with 4 separate cultures. [ 3 H]Thymidine studies were conducted in subconfluent monolayers. However, to ensure that changes in collagen and protein synthesis were not due to a decrease in cell number, these experiments were conducted in confluent monolayers of cells in which changes in cell number were precluded. Cell counting was performed in cells treated in parallel to the cells used for the collagen and total protein synthesis, and the data were normalized to cell number.
Cell Proliferation
Cell counting was performed as a direct measure of cell proliferation. Trypsinized SMCs were suspended in DMEM/F12 containing 10% FCS and plated in a 24-well culture dish at a density of 1ϫ10 4 cells per well. After incubation for 18 hours, the cells were fed DMEM containing 0.25% FCS for 48 hours to growth arrest the cells. SMCs were then treated every 24 hours for 4 days with DMEM supplemented with 2.5% FCS and containing or lacking various treatments, as described above. The treatments were terminated on day 5, and cells were dislodged with trypsin-EDTA, diluted in Isoton-II, and counted with a Coulter counter. Aliquots from 3 wells were counted for each group with 4 separate cultures.
Adenosine and cAMP Measurements
Monolayers of SMCs grown to confluence in 12-well culture plates were washed twice with PBS and then incubated with buffered (HEPES, 25 mmol/L; NaHCO 3 , 13 mmol/L) PBS containing or lacking the above treatments. After 10 minutes or 4 hours of incubation, the supernatants were collected, and the cells were treated with 1 mL of ice-cold propanediol and pooled together with the supernatants. Total adenosine and cAMP levels were then analyzed by high-performance liquid chromatography with a previously described method. 9 In cells grown in parallel and treated similarly, the monolayers were inspected microscopically for intactness, the number of cells were counted, and the data were normalized to cell number.
Statistical Analysis
All experiments were performed in triplicate or quadruplicate with 4 separate cultures, and all data are presented as meanϮSEM. Statistical analysis was performed with ANOVA, paired Student's t test, or Fisher's least significant difference test, as appropriate. A value of PϽ0.05 was considered statistically significant.
Results
Treatment with FCS significantly (PϽ0.05, paired Student's t test) stimulated 
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To investigate whether adenosine and its receptors participate in mediating the inhibitory effects of estradiol, the effects of 17␤-estradiol (0.001 to 10 mol/L) on SMC growth were examined in the presence and absence of DPCPX (10 nmol/L; a specific A 1 adenosine receptor antagonist), KF17837 (10 nmol/L; a specific A 2 adenosine receptor antagonist), and DPSPX (10 nmol/L; a nonselective A 1 /A 2 adenosine receptor antagonist To investigate whether cAMP and cAMP-dependent protein kinase A participate in mediating the inhibitory effects of estradiol, the effects of 17␤-estradiol (0.001 to 10 mol/L) on SMC growth were examined in the presence and absence of DDA (10 mol/L; an adenylyl cyclase inhibitor) and Rp- ]leucine incorporation and cell number were significantly reduced in SMCs pretreated with DDA but not Rp-cAMP, and the inhibitory curves for 17␤-estradiol were shifted to the right (Figures 1B through  4B ; PϽ0.05, ANOVA followed by Fisher's least significant test).
To further investigate the role of cAMP and adenosine in mediating the inhibitory effects of estradiol on SMC growth, the effects of 17␤-estradiol (1 mol/L) on SMC growth were investigated in the presence and absence of forskolin (5 mol/L; activates adenylyl cyclase and induces endogenous cAMP levels) and EHNA (10 mol/L; prevents adenosine catabolism by inhibiting adenosine deaminase) plus iodotubericidin (0.1 mol/L; elevates adenosine levels by inhibiting adenosine kinase activity). Analysis of the data by ANOVA followed by Fisher's least significant test revealed that the inhibitory effects of estradiol on [
3 H]thymidine incorporation and cell proliferation were significantly enhanced by either forskolin or EHNA plus iodotubericidin ( Figure 5A and 5B). Moreover, the increase in the inhibitory effect of 17␤-estradiol by forskolin or EHNA plus iodotubericidin was abolished in SMCs pretreated with DDA (10 mol/L), DPSPX (10 nmol/L), or KF17837 (10 nmol/L) but not DPCPX (10 nmol/L) ( Figure 5A and 5B).
To ascertain whether the inhibitory effects of 17␤-estradiol were mediated by cAMP-derived adenosine, we assayed the levels of cAMP and adenosine in SMCs treated for 4 hours with various treatments (Figure 6 ). Compared with SMCs treated with PBS, both cAMP and adenosine levels increased significantly (paired Student's t test) in SMCs treated with 17␤-estradiol or forskolin. Moreover, the ability of 17␤-estradiol to increase adenosine levels was enhanced significantly (PϽ0.05) by cotreatment with forskolin or EHNA plus iodotubericidin. The stimulatory effects of 17␤-estradiol with and without forskolin or EHNA plus iodotubericidin on cAMP and adenosine levels were inhibited by DDA but not by DPSPX, DPCPX, KF17837, or Rp-cAMP (ANOVA followed by Fisher's least significant test).
To determine whether the effects of 17␤-estradiol (1 mol/L) on cAMP and adenosine levels were estrogen receptor mediated and nongenomic in nature, cAMP and adenosine levels were measured in SMCs treated for 10 minutes with 17␤-estradiol in the presence and absence of ICI 182780 (50 mol/L; an estrogen receptor antagonist without partial agonist activity) and cycloheximide (10 mol/L). Treatment of SMCs for 10 minutes with 17␤-estradiol increased cAMP as well as adenosine levels by almost 100%, and the stimulatory effects of 17␤-estradiol were blocked by ICI 182780 but not cycloheximide (data not shown).
Discussion
Our previous studies establish that SMCs synthesize adenosine and that exogenous as well as endogenous (SMCderived) adenosine inhibits FCS-induced growth. [5] [6] [7] Moreover, our prior studies demonstrate that SMCs express an active cAMP-adenosine pathway, ie, the conversion of cAMP to AMP and then to adenosine by phosphodiesterase and 5Ј-nucleotidase, respectively. 6 Because 17␤-estradiol is known to increase cAMP levels in SMCs, we hypothesized that the cAMP-adenosine pathway participates in mediating the well-known inhibitory effects of 17␤-estradiol on SMC growth. [1] [2] [3] [4] The results of the present study indicate that adenosine importantly contributes to the inhibitory effects of 17␤-estradiol on SMC growth. Our findings that the inhibitory effects of 17␤-estradiol on SMC growth are significantly attenuated by KF17837, a specific A 2 adenosine receptor antagonist, and by DPSPX, a nonselective A 2 adenosine receptor antagonist, but not by DPCPX, a selective A 1 adenosine receptor antagonist, suggest that 17␤-estradiol inhibits SMC growth by a mechanism involving interactions of endogenous adenosine with A 2 adenosine receptors. Additional evidence for the role of adenosine in mediating the inhibitory effects of 17␤-estradiol are our observations that (1) treatment of SMCs with 17␤-estradiol increases adenosine levels; (2) the effects of 17␤-estradiol on SMC growth and adenosine levels are enhanced by EHNA and iodotubericidin, drugs that elevate endogenous adenosine levels by inhibiting adenosine deaminase and adenosine kinase activity, respectively; and (3) DPSPX and KF17837, but not DPCPX, block the inhibitory effects of 17␤-estradiol on SMC growth even in the presence of EHNA and iodotubericidin without influencing adenosine levels. Together, these findings provide evidence that 17␤-estradiol inhibits vascular SMC growth in part by increasing adenosine levels.
The results of the present study suggest that increased adenosine synthesis in response to 17␤-estradiol is derived from cAMP. This hypothesis is supported by our findings that 17␤-estradiol causes a concomitant increase in cAMP and adenosine levels and that inhibition of adenylyl cyclase attenuates 17␤-estradiol-induced increases in cAMP and adenosine levels. The observation that inhibition of adenylyl cyclase also attenuates the growth-inhibitory effects of 17␤-estradiol suggests that cAMP-derived adenosine participates in the mechanism by which 17␤-estradiol inhibits SMC growth.
The fact that inhibition of adenylyl cyclase prevents 17␤-estradiol-induced inhibition of vascular SMC growth is consistent with 2 hypotheses that are not mutually exclusive: (1) 17␤-estradiol increases cAMP levels, and the direct intracellular effects of cAMP via cAMP-dependent protein kinase mediates the growth-inhibitory actions of 17␤-estradiol; and (2) 17␤-estradiol increases cAMP levels, and cAMP is metabolized to adenosine, which mediates the growth-inhibitory actions of 17␤-estradiol. The present study supports the second, but not the first, mechanism since we observe that the growth-inhibitory effects of 17␤-estradiol are reduced by antagonism of adenosine receptors but are not reduced by blockade of cAMP-dependent protein kinase with Rp-cAMP. In this regard, our previous studies demonstrate that adenosine stimulates nitric oxide release from vascular SMCs via a pathway not involving adenylyl cyclase/protein kinase A. 10 Since nitric oxide inhibits SMC proliferation, 11 this provides a protein kinase A-independent pathway via which 17␤-estradiol-induced adenosine could inhibit SMC growth.
Although the present studies focus on vascular SMCs, our previous studies demonstrate that not only vascular SMCs 6 but also mesangial cells 12 and cardiac fibroblasts 13 express the cAMP-adenosine pathway. Moreover, in all these cell types, cAMP-derived adenosine inhibits mitogen-induced cell growth. 6, 12, 13 Therefore, it is possible that the mechanism revealed by the present study applies to a broader array of cardiovascular tissues/cell types.
The mechanism uncovered by the present study should be viewed in a wider context. Other mechanisms by which 17␤-estradiol induces its protective effects on the cardiovascular system include reducing apoptosis and inducing endothelial cell recovery and growth, improving endothelialmediated degradation of LDL cholesterol, suppressing collagen and elastin synthesis, restoring endotheliumdependent vasodilator mechanisms after injury, reducing LDL levels, increasing HDL levels, preventing oxidation of LDL, releasing prostaglandins from vascular endothelial cells, reducing the adhesion of activated monocytes to the endothelium by inhibiting the expression of adhesion molecules, inhibiting cardiac fibroblast growth, and inhibiting MAP kinase activity. 2, 14 Our finding that 17␤-estradiol induces antiproliferative effects on SMCs via the cAMP-adenosine pathway provides evidence of yet another mechanism by which 17␤-estradiol induces cardioprotective effects.
The effects of 17␤-estradiol on cell function are thought to be mediated via estrogen receptor ␣ and ␤ and to involve genomic pathways. The finding that treatment of SMCs with 17␤-estradiol for 10 minutes increases cAMP and adenosine levels by Ϸ100% and that these effects are blocked by the estrogen receptor antagonist ICI 182780, but not cycloheximide, suggests that stimulatory effects of 17␤-estradiol on cAMP/adenosine synthesis are mediated via a nongenomic pathway linked to estrogen receptor ␣ or ␤.
What is the relevance of our in vitro finding that the cAMP-adenosine pathway participates in mediating the inhibitory effects of 17␤-estradiol on SMC growth? With the onset of menopause, circulating 17␤-estradiol levels decrease, and this would decrease adenosine levels in the vascular wall. Thus, the increased incidence of cardiovascular disease in postmenopausal women may be due in part to a reduction in the vascular levels of the cardioprotective autacoid adenosine.
In conclusion, we provide evidence that the cAMP-adenosine pathway, via activation of A 2 adenosine receptors, participates in mediating the inhibitory effects of 17␤-estradiol on vascular SMC growth (Figure 7) . Thus, the cAMP-adenosine pathway may importantly contribute to the vasoprotective and cardioprotective effects of 17␤-estradiol. 
